Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study - Takeaways - MDSpire

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • By

  • Cosimo Ruggiero

  • Giusy Russo

  • Denis Cozzi

  • Danila Volpe

  • Silvia Ceccanti

  • Paola Papoff

  • Miriam D’Orsi

  • Tonia Raso

  • Giulia Mancuso

  • Salvatore Oliva

  • May 14, 2026

  • 0 min

Share

  • 1

    Oral viscous budesonide (OVB) maintenance therapy significantly improves dilation-free survival in children post-esophageal atresia surgery.

  • 2

    At 6 months, dilation-free survival was 91% in the OVB group compared to 50% in controls, indicating a substantial benefit.

  • 3

    Dilation recurrence rates were 25% in the OVB group versus 70% in controls, highlighting OVB's effectiveness in reducing recurrence.

  • 4

    Maintenance OVB therapy was associated with a longer median time to recurrence of dilation, suggesting prolonged benefits.

  • 5

    No systemic adverse effects were reported, supporting the safety of OVB as a maintenance therapy for recurrent anastomotic stricture.

Original Source(s)

Maintenance oral viscous budesonide reduces dilation recurrence after esophageal atresia repair: a prospective clinical study

  • by Cosimo Ruggiero, Giusy Russo, Denis Cozzi, Danila Volpe, Silvia Ceccanti, Paola Papoff, Miriam D’Orsi, Tonia Raso, Giulia Mancuso, Salvatore Oliva

  • May 14, 2026

Related Content

Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis

Stool Withholding at School Among Children in the Netherlands

Predictors and Outcomes of Subclinical Inflammation in Pediatric Patients with Familial Mediterranean Fever: A Retrospective Cohort Study from a Single Center